Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022, Nov 8. (Engl / Fr)
MVdeltaC shows encouraging results in several preclinical models of solid tumors such as mesothelioma, bladder cancer and neuroblastoma Paris, France, November 2, 2022 – Oncovita, a French biotech company specialized in therapeutic and prophylactic vaccines, today announces that the main preclinical data on MVdeltaC, its first therapeutic vaccine candidate